Seeking Alpha

Andrew Colburn's  Instablog

Andrew Colburn
Send Message
I studied Political Science at Edinboro University with an interest in international relations (particularly China). My first year of investing (2012) I managed 280% growth.
  • Invailidation Of Lovaza Patent Has No Bearing On Amarin 6 comments
    Sep 12, 2013 1:18 PM | about stocks: AMRN

    Apparently Wall Street likes to read headlines without doing much due diligence. So here is the case in a nut shell.

    Teva found a way to invalidate the patent by finding out Dr. Victor Skrinska of St. Vincent Charity Hospital used liquid vials of "K-80" ethyl ester composition produced by Norsk Hydro (the predecessor of Pronova) back in 1987. There was no clinical investigation tied to the use thus invalidating the patent on prior public use.

    From the court document:

    "Teva asserts the testing which Skrinska performed constitutes an invalidating public use because, in its view, any use of a claimed invention can be invalidating. An invalidating public use need not be the intended use of the invention disclosed or claimed in the patent as long as the invention is fully disclosed without restriction."

    and

    Section 102(b) of Title 35 of the U.S. Code states:

    A person shall be entitled to a patent unless. . . (b) the invention was . . . in public use . . . in this country, more than one year prior to the date of the application for patent in the United States.

    In short, this has no bearing on AMRN or its extensive patent portfolio. The market reaction to this news is, for a lack of words, stupid.

    Disclosure: I am long AMRN.

    Additional disclosure: My father is long AMRN as well.

    Themes: Biotechnology Stocks: AMRN
Back To Andrew Colburn's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (6)
Track new comments
  • Spiritwarrior
    , contributor
    Comments (25) | Send Message
     
    Thanks for the quick post, it's getting SO OLD watching AMRN pps drop because of uneducated, uninformed investors. WS knows what's going on, they just play dumb better then I've ever seen but make bucko $$$$ doing so.

     

    Who cares is L can now be generic, V is far superior and doctors will figure it out!

     

    This drop is ridiculous just like all the AMRN pps drops but it's all good, no worries here never have been. AMRN is a safe bet regardless of all the shenanigans and bears with low IQ's who can't figure out why they are bears.
    12 Sep 2013, 01:25 PM Reply Like
  • Red Acre Investments
    , contributor
    Comments (486) | Send Message
     
    While it has no bearing on AMRN's intellectual property, the issue is that generic lovaza would be priced more cheaply than Lovaza and Vasceap - thus creating pricing pressure on AMRN.

     

    All of these things are a long way off compared to the 10/16 advisory committee vote.
    12 Sep 2013, 01:26 PM Reply Like
  • Jolk
    , contributor
    Comments (216) | Send Message
     
    The availability of Generic Lovaza for prescribing into the ANCHOR population should be a point of concern from MDs who want broader treatment options that don't affect LDL-C levels or have an atrial fibrillation warning.

     

    Some have already come out speaking for Vascepa because of the frequent off-label use of Lovaza... Why delay Vascepa if you're going to have a cheaper, inferior generic being prescribed to these ANCHOR patients?
    12 Sep 2013, 01:29 PM Reply Like
  • Andrew Colburn
    , contributor
    Comments (134) | Send Message
     
    Author’s reply » Red Acre, I doubt it will have that great of an impact on sales (if noticeable at all). The sticking point for Vascepa are the clinical results which is why cardiologists visited so far by the sales reps have switched from not only Lovaza but OTC fish oil to Vascepa as well. The co-pay difference of a few dollars/month compared to differing benefit I don't think will deter docs. (my opinion of course)
    12 Sep 2013, 01:52 PM Reply Like
  • Scientist on Stocks
    , contributor
    Comments (182) | Send Message
     
    ''..Additional disclosure: My father is long AMRN as well...''

     

    i loved this !
    15 Sep 2013, 01:21 AM Reply Like
  • Andrew Colburn
    , contributor
    Comments (134) | Send Message
     
    Author’s reply » Not sure if your making fun of it or not, but I'm all for transparency. Since I handle my dad's IRA I thought I should disclose it.
    15 Sep 2013, 05:05 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.